Table 7.
Author | Year of Publication | Studies | Sample Size (No. of Events/No. of Patients) | Type of Effect | P for Heterogeneity | Main Results |
---|---|---|---|---|---|---|
Birns et al454 | 2006 | PROGRESS SCOPE SHEP Syst-Eur | 642/18 196 | Fixed | 0.18 | 0.89 (95% CI 0.75–1.04); P=0.15 |
Feigin et al453 | 2005 | PROGRESS SCOPE SHEP Syst-Eur | 883/23 505 | Random | 0.06 | 0.80 (95% CI 0.63–1.02); P=0.07 |
Peters et al444 | 2008 | HYVET PROGRESS SHEP Syst-Eur | 786/16 595 | Random | 0.49 | 0·87 (95% CI 0.76–1.00);P=0.045 |
McGuinness et al456 | 2008 | SCOPE SHEP Syst-Eur | 232/15 295 | Fixed | 0.16 | 0.89 (95% CI 0.69–1.16); P=0.38 |
McGuinness et al455 | 2009 | HYVET SCOPE SHEP Syst-Eur | 495/15 427 | Fixed | 0.30 | 0.89 (95% CI 0.74–1.07); P=0.21 |
PROGRESS indicates Perindopril Protection Against Recurrent Stroke Study; SCOPE, Study on Cognition and Prognosis in the Elderly; SHEP, Systolic Hypertension in the Elderly Program; Syst-Eur, Systolic Hypertension in Europe; CI, confidence interval; and HYVET, Hypertension in the Very Elderly Trial.